Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.
Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.